Pancreatic cancer (PDAC) is the fourth leading cause of cancer-related mortality in the Western world and, even in 2014, a\ntherapeutic challenge. The only chance for long-term survival is radical surgical resection followed by adjuvant chemotherapy\nwhich can be performed in about 20% of all PDAC patients by the time of diagnosis. As pancreatic surgery has significantly changed\nduring the past years, extended operations, including vascular resections, have become more frequently performed in specialized\ncentres and the border of resectability has been pushed forward to achieve a potentially curative approach in the respective patients\nin combination with neoadjuvant and adjuvant treatment strategies. In contrast to adjuvant treatment which has to be regarded\nas a cornerstone to achieve long-term survival after resection, neoadjuvant treatment strategies for locally advanced findings are\ncurrently under debate. This overview summarizes the possibilities and evidence of vascular, namely, venous and arterial, resections\nin PDAC surgery.
Loading....